NCT05858632RecruitingPhase 4
Immune Spatial Features of Guselkumab Cutaneous Response
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 4 May 2023
- Start date
- 1 Jul 2023
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- University of California, San Francisco
- Diseases
- Psoriasis
- NCT number
- NCT05858632
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 10
- From 1 Jul 2023 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- tuberculosis or other active serious infection
- active systemic malignancy.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Other
- taking systemic immunosuppressives in the last 4 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- breast-feeding
- Males who are trying to conceive
- \-
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.